Literature DB >> 8670554

Cognitive decline in patients with Alzheimer's disease, vascular dementia and senile dementia of Lewy body type.

C Ballard1, A Patel, F Oyebode, G Wilcock.   

Abstract

One hundred and twenty-four patients with DSM-III-R dementia were assessed with a standardized battery which included the Geriatric Mental State Schedule, the History and Aetiology Schedule, the Secondary Dementia Schedule and the CAMCOG. Patients with Alzheimer's disease, vascular dementia and senile dementia of Lewy body type (SDLT) all had a similar degree of cognitive impairment at the time of the baseline interview. Patients with Alzheimer's disease and vascular dementia each experienced a mean decline of 27 points in patients with SDLT. Patients with SDLT had a significantly greater decline of verbal fluency than both the other groups. Women were significantly more impaired than men at the time of the baseline assessment but experienced a similar decline during the year of follow-up.

Entities:  

Mesh:

Year:  1996        PMID: 8670554     DOI: 10.1093/ageing/25.3.209

Source DB:  PubMed          Journal:  Age Ageing        ISSN: 0002-0729            Impact factor:   10.668


  10 in total

Review 1.  The CARE pathway model for dementia: psychosocial and rehabilitative strategies for care in young-onset dementias.

Authors:  Darby Morhardt; Sandra Weintraub; Becky Khayum; Jaimie Robinson; Jennifer Medina; Mary O'Hara; Marsel Mesulam; Emily J Rogalski
Journal:  Psychiatr Clin North Am       Date:  2015-03-07

2.  Recognition memory span in autopsy-confirmed Dementia with Lewy Bodies and Alzheimer's Disease.

Authors:  David P Salmon; William C Heindel; Joanne M Hamilton; J Vincent Filoteo; Varun Cidambi; Lawrence A Hansen; Eliezer Masliah; Douglas Galasko
Journal:  Neuropsychologia       Date:  2015-07-14       Impact factor: 3.139

3.  Volumetric MRI predicts rate of cognitive decline related to AD and cerebrovascular disease.

Authors:  D Mungas; B R Reed; W J Jagust; C DeCarli; W J Mack; J H Kramer; M W Weiner; N Schuff; H C Chui
Journal:  Neurology       Date:  2002-09-24       Impact factor: 9.910

4.  Hippocampal α-Synuclein in Dementia with Lewy Bodies Contributes to Memory Impairment and Is Consistent with Spread of Pathology.

Authors:  David H Adamowicz; Subhojit Roy; David P Salmon; Douglas R Galasko; Lawrence A Hansen; Eliezer Masliah; Fred H Gage
Journal:  J Neurosci       Date:  2016-12-30       Impact factor: 6.167

5.  Are hallucinations and extrapyramidal signs associated with a steeper cognitive decline in degenerative dementia patients?

Authors:  E Capitani; A Francescani; H Spinnler
Journal:  Neurol Sci       Date:  2007-10-31       Impact factor: 3.307

6.  CSF prion protein concentration and cognition in patients with Alzheimer disease.

Authors:  Christian Schmidt; Svetlana Artjomova; Martin Hoeschel; Inga Zerr
Journal:  Prion       Date:  2013-02-13       Impact factor: 3.931

Review 7.  Dementia with Lewy bodies.

Authors:  Tanis J Ferman; Bradley F Boeve
Journal:  Neurol Clin       Date:  2007-08       Impact factor: 3.806

8.  Long-term donepezil use for dementia with Lewy bodies: results from an open-label extension of Phase III trial.

Authors:  Etsuro Mori; Manabu Ikeda; Reiko Nagai; Kazutaka Matsuo; Masaki Nakagawa; Kenji Kosaka
Journal:  Alzheimers Res Ther       Date:  2015-02-03       Impact factor: 6.982

9.  A systematic review of cognitive decline in dementia with Lewy bodies versus Alzheimer's disease.

Authors:  Monica H Breitve; Luiza J Chwiszczuk; Minna J Hynninen; Arvid Rongve; Kolbjørn Brønnick; Carmen Janvin; Dag Aarsland
Journal:  Alzheimers Res Ther       Date:  2014-09-16       Impact factor: 6.982

10.  Long-term cognitive outcome of Alzheimer's disease and dementia with Lewy bodies: dual disease is worse.

Authors:  Frédéric Blanc; Rachid Mahmoudi; Thérèse Jonveaux; Jean Galmiche; Gilles Chopard; Benjamin Cretin; Catherine Demuynck; Catherine Martin-Hunyadi; Nathalie Philippi; François Sellal; Jean-Marc Michel; Gregory Tio; Melanie Stackfleth; Pierre Vandel; Eloi Magnin; Jean-Luc Novella; Georges Kaltenbach; Athanase Benetos; Erik A Sauleau
Journal:  Alzheimers Res Ther       Date:  2017-06-27       Impact factor: 6.982

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.